CN Patent

CN117062911A — 肌萎缩性脊髓侧索硬化症的治疗

Assigned to Bojian Massachusetts Co ltd · Expires 2023-11-14 · 3y expired

What this patent protects

本公开提供了神经丝轻链水平在选择具有过氧化物歧化酶1(SOD1)基因的突变的受试者以用SOD1靶向反义寡核苷酸或其盐进行治疗中的用途。所述公开的方法可用于治疗肌萎缩性脊髓侧索硬化症，包括临床上症状发生前肌萎缩性脊髓侧索硬化症。

USPTO Abstract

本公开提供了神经丝轻链水平在选择具有过氧化物歧化酶1(SOD1)基因的突变的受试者以用SOD1靶向反义寡核苷酸或其盐进行治疗中的用途。所述公开的方法可用于治疗肌萎缩性脊髓侧索硬化症，包括临床上症状发生前肌萎缩性脊髓侧索硬化症。

Drugs covered by this patent

Patent Metadata

Patent number
CN117062911A
Jurisdiction
CN
Classification
—
Expires
2023-11-14
Drug substance claim
No
Drug product claim
No
Assignee
Bojian Massachusetts Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.